Company intelligence / Profile preview

FinovUP

Burgdorf, Bern, Switzerlandfinovup.fr ↗

Ownership: Private
Development stage: Other

Overview

Bemfola®, the lead product of Finox Biotech, demonstrated bioequivalence to reference r-FSH products and was approved by the European Medicines Agency for infertility treatment. It featured an innovative single-use injector pen designed for ease of use and patient compliance. The product reached commercial stage with launches across Europe and MENA prior to acquisition by Gedeon Richter

Therapeutic areas: Women's Health
Modalities: Recombinant protein
Industry: Biotech

Partnerships

Genpharm Services – distribution/commercialization partnership for Bemfola® in Middle East/North Africa region

Beyond the preview

Go deeper on FinovUP.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FinovUP.

Explore the full profile